Calliditas Therapeutics (CALT) has released an update.
Calliditas Therapeutics, a Stockholm-based biopharma company, is preparing to delist from Nasdaq Stockholm and the Nasdaq Global Select Market following Asahi Kasei’s acquisition of over 90% of its shares. The company will apply for delisting, with the last trading day to be announced post-confirmation from Nasdaq Stockholm. Additionally, an Extraordinary General Meeting is scheduled for September 30, 2024, to elect a new Board of Directors.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
